Fuzheng Kang-Ai inhibits NSCLC cell proliferation via regulating hsa_circ_0048091/hsa-miR-378g/ARRDC3 pathway.
Tang Q, Wang X, Zhou Q, Li Q, Yang X, Xu M, Wang R, Chen J, Wu W, Wang S.
Tang Q, et al.
Phytomedicine. 2023 Jun;114:154819. doi: 10.1016/j.phymed.2023.154819. Epub 2023 Apr 11.
Phytomedicine. 2023.
PMID: 37062135
Free article.
Therefore, more safe and effective drugs are needed. PURPOSE: Fuzheng Kang-Ai (FZKA for short) has been applied as an adjuvant treatment in advanced Non-Small Cell Lung Cancer (NSCLC) patients for decades in China, showing a definitive effect with minimal toxicities …
Therefore, more safe and effective drugs are needed. PURPOSE: Fuzheng Kang-Ai (FZKA for short) has been applied as an adjuvant …